Biomarkers

Biomarkers Market Outlook

The global biomarkers market is projected to reach approximately USD 51 billion by 2035, growing at a CAGR of around 12% during the forecast period from 2025 to 2035. This substantial growth can be attributed to the increasing prevalence of chronic diseases, advancements in biotechnological research, and a growing emphasis on personalized medicine. Furthermore, the rising demand for early disease detection and the increasing investment in biomarker discovery and development are also driving factors contributing to the market's expansion. The integration of innovative technologies such as artificial intelligence in biomarker analysis is expected to enhance the efficiency and accuracy of diagnostic solutions, further propelling market growth. Additionally, the growing public awareness regarding preventive healthcare practices and the significance of biomarkers in treatment outcomes are expected to foster a favorable environment for market growth.

Growth Factor of the Market

The biomarkers market is experiencing a robust growth trajectory, driven predominantly by the surge in chronic diseases and the escalation of healthcare costs, which necessitate targeted and efficient diagnostics. The increasing investment in research and development activities focused on biomarker discovery is fostering innovation and enabling the introduction of novel diagnostic tools. Furthermore, advancements in technology, especially in genomics and proteomics, are playing a pivotal role in enhancing the capabilities and applications of biomarkers in clinical settings. The growing trend of personalized medicine is also a significant growth factor, as biomarkers enable clinicians to tailor treatments based on individual patient profiles, leading to improved therapeutic outcomes. Additionally, the integration of digital health solutions, such as telemedicine and mobile health applications, is facilitating better patient management and driving the demand for biomarkers.

Key Highlights of the Market

• The biomarkers market is projected to reach USD 51 billion by 2035, with a CAGR of 12% from 2025 to 2035.
• Personalized medicine is becoming a prominent trend, fostering the demand for precise biomarker applications.
• Technological advancements in genomic and proteomic research are enhancing biomarker discovery.
• Increased investment in R&D activities, particularly in drug development, is boosting market growth.
• Healthcare professionals are utilizing biomarkers for accurate disease diagnosis, leading to improved patient outcomes.

By Product Type

Consumables:

In the biomarkers market, consumables represent a significant segment, encompassing various products such as assay kits, reagents, and laboratory supplies used in the biomarker testing process. This segment is driven by the increasing demand for rapid and accurate diagnostic tests, particularly in laboratories and clinical settings. The continuous advancements in technology have led to the development of highly sensitive and specific consumables, further enhancing their adoption in biomarker analysis. Moreover, the rising focus on research and development in biomarker discovery is contributing to the growth of this segment, as laboratories require a wide array of consumable products to conduct extensive testing and validation. As the healthcare industry continues to evolve towards precision medicine, the demand for high-quality consumables is expected to rise significantly, driving the overall growth of this segment.

Services:

The services segment within the biomarkers market includes a wide range of offerings, such as testing services, consulting services for biomarker development, and clinical trial services. This segment is gaining traction due to the increasing complexity of biomarker testing, which necessitates specialized knowledge and expertise. With the surge in personalized medicine and targeted therapies, healthcare providers are increasingly seeking third-party services to enhance their biomarker testing capabilities. Moreover, contract research organizations (CROs) are playing a crucial role in offering specialized services in biomarker validation, which is essential for the successful commercialization of new diagnostics. The continuous evolution of regulatory frameworks and the need for compliance in biomarker testing further underscore the importance of services in this market, making them a vital component of the overall biomarker landscape.

Software:

The software segment in the biomarkers market is witnessing significant growth due to the increasing reliance on data analytics and bioinformatics in biomarker discovery and validation. Advanced software solutions are being developed to analyze vast amounts of biological data, enabling researchers and clinicians to identify potential biomarkers efficiently. These tools not only streamline the data interpretation process but also enhance the accuracy of results, leading to more reliable diagnostic outcomes. Additionally, the integration of artificial intelligence and machine learning algorithms into software solutions is revolutionizing biomarker research by providing predictive models that can forecast patient responses to treatments. As healthcare organizations increasingly adopt digital solutions for biomarker analysis, the software segment is poised for substantial growth, driven by the need for enhanced data management and analytics capabilities.

By Application

Diagnostics:

Diagnostics is one of the primary applications of biomarkers, playing a pivotal role in the early detection and monitoring of various diseases. The use of biomarkers in diagnostics enables healthcare professionals to identify disease states with greater accuracy and speed, which is particularly vital in conditions such as cancer, where early intervention can significantly impact patient outcomes. The rising prevalence of chronic diseases and the increasing demand for personalized healthcare solutions are driving the adoption of biomarker-based diagnostic tests across clinical settings. Furthermore, the development of novel biomarkers that can provide insights into disease mechanisms is enhancing diagnostic capabilities and contributing to the growth of this application area. As diagnostic technologies continue to evolve, the importance of biomarkers in ensuring precise and timely diagnoses will only increase.

Drug Discovery and Development:

In the realm of drug discovery and development, biomarkers serve as critical tools for identifying potential drug targets, assessing therapeutic efficacy, and predicting patient responses to treatments. The integration of biomarkers in clinical trials has become a standard practice, as they enable researchers to stratify patient populations and ensure that the right therapies are administered to the right patients. This targeted approach not only enhances the likelihood of successful drug development but also significantly reduces the time and costs associated with bringing new therapies to market. Moreover, the increasing focus on personalized medicine is driving the demand for biomarkers in drug development, as pharmaceutical companies seek to create targeted therapies that improve treatment outcomes. As the pharmaceutical industry continues to embrace biomarker-driven strategies, this application area is expected to witness substantial growth.

Personalized Medicine:

The application of biomarkers in personalized medicine is transforming the healthcare landscape by enabling tailored treatment strategies based on individual patient characteristics. Biomarkers facilitate the identification of patients who are most likely to benefit from specific therapies, thereby improving treatment efficacy and minimizing adverse effects. This shift towards personalized medicine is being driven by advancements in genomic technologies and a deeper understanding of disease pathology, allowing for the development of targeted therapies that are more aligned with patients' unique biological profiles. As healthcare systems around the world increasingly prioritize personalized approaches to treatment, the demand for biomarkers in this application area is expected to grow substantially, paving the way for more effective and individualized healthcare solutions.

By End User

Hospitals:

Hospitals are significant end users of biomarkers, utilizing them for disease diagnosis, treatment monitoring, and patient management. The integration of biomarker testing into routine clinical practice has become increasingly common, as hospitals seek to enhance patient outcomes through timely and accurate diagnostics. Furthermore, hospitals are increasingly adopting advanced biomarker technologies, such as next-generation sequencing and liquid biopsy, enabling them to offer comprehensive diagnostic services. The growing emphasis on precision medicine in hospital settings is also driving the demand for biomarker applications, as healthcare providers aim to deliver targeted therapies that align with patients' individual needs. As hospitals continue to invest in innovative biomarker solutions, this end-user segment is expected to experience substantial growth.

Diagnostic Laboratories:

Diagnostic laboratories play a crucial role in the biomarkers market by providing essential testing services that facilitate disease diagnosis and monitoring. As the demand for rapid and accurate diagnostic tests continues to rise, laboratories are increasingly adopting biomarker testing technologies to enhance their service offerings. The growing prevalence of chronic diseases, coupled with the increasing need for early detection and timely intervention, is driving the demand for biomarker testing in diagnostic laboratories. Additionally, advancements in laboratory automation and informatics are enabling laboratories to process biomarker tests more efficiently, further enhancing their capabilities. As the healthcare landscape evolves, diagnostic laboratories will continue to be pivotal in the biomarker ecosystem, ensuring that patients receive accurate and timely diagnostic information.

Pharmaceutical and Biotechnology Companies:

Pharmaceutical and biotechnology companies are significant contributors to the biomarkers market, leveraging biomarkers to streamline drug discovery processes and enhance the efficacy of therapeutic interventions. These companies utilize biomarkers for various purposes, including identifying promising drug candidates, monitoring treatment responses, and conducting valuable pharmacogenomic research. The growing emphasis on personalized medicine in the pharmaceutical industry is propelling the adoption of biomarker strategies, as companies seek to develop targeted therapies that improve patient outcomes. Moreover, the collaboration between pharmaceutical firms and research institutions to explore novel biomarkers is fostering innovation and accelerating the development of new diagnostic tools. As these companies continue to invest in biomarker research and development, they are expected to play a pivotal role in shaping the future of the biomarkers market.

CROs:

Contract Research Organizations (CROs) are becoming increasingly important in the biomarkers market, offering specialized services that support the development and validation of biomarker-based diagnostics. These organizations provide expertise in various areas, including study design, data analysis, and regulatory compliance, facilitating the successful conduct of clinical trials involving biomarkers. As the complexity of biomarker testing increases, CROs play a crucial role in assisting pharmaceutical and biotechnology companies in navigating the challenges associated with biomarker research. Furthermore, the rising trend of outsourcing in the pharmaceutical industry is driving the demand for CRO services, as companies seek to leverage external expertise while focusing on core competencies. As the biomarkers market continues to expand, CROs are expected to remain key players in driving innovation and ensuring the successful implementation of biomarker strategies.

By Disease Indication

Cancer:

Cancer is one of the leading disease indications driving the growth of the biomarkers market, as biomarkers play a crucial role in the early detection, diagnosis, and treatment monitoring of various cancer types. The increasing prevalence of cancer globally is propelling the demand for innovative biomarker-based diagnostic solutions that can facilitate timely interventions and improve patient outcomes. Advances in genomic and proteomic technologies have led to the discovery of novel cancer biomarkers that enable personalized treatment approaches, allowing clinicians to select the most effective therapies for individual patients. Furthermore, the rising focus on targeted therapies and immunotherapy in oncology is further driving the adoption of biomarkers, as these treatment modalities rely heavily on biomarker identification for patient stratification. As research in cancer biomarkers continues to evolve, this disease indication is expected to remain a significant driver of market growth.

Cardiovascular Disorders:

The increasing incidence of cardiovascular disorders is significantly contributing to the growth of the biomarkers market, as biomarkers are essential for risk stratification, early detection, and treatment monitoring in cardiovascular diseases. The development of novel biomarkers that can provide insights into cardiovascular health is enabling healthcare professionals to make informed decisions regarding patient management and treatment strategies. Furthermore, biomarkers play a vital role in assessing the effectiveness of interventions and predicting patient outcomes in cardiovascular care. As the global burden of cardiovascular diseases continues to rise, the demand for biomarker-based diagnostic solutions is expected to expand, driving innovation in this area and enhancing the overall management of cardiovascular health.

Infectious Diseases:

Infectious diseases represent a significant disease indication within the biomarkers market, as biomarkers are crucial for the rapid diagnosis and monitoring of various infectious agents. The recent global health challenges posed by pandemics have underscored the importance of timely and accurate diagnostic testing, further driving the demand for biomarkers in this domain. Advances in molecular diagnostics and immunoassays are enabling the development of novel biomarkers that can detect infectious agents with high sensitivity and specificity. Additionally, biomarkers play a critical role in epidemiological studies and vaccine development, as they can help in tracking disease outbreaks and evaluating immune responses. As the landscape of infectious diseases evolves, the biomarkers market is expected to witness substantial growth in this indication.

Neurological Disorders:

Neurological disorders are increasingly being recognized as a vital area for biomarker research, as biomarkers can provide valuable insights into the diagnosis and management of conditions such as Alzheimer's disease, Parkinson's disease, and multiple sclerosis. The complexity of neurological diseases has created a demand for innovative biomarker solutions that can aid in early detection and monitoring of disease progression. Recent advancements in neuroimaging and biomarker discovery techniques have led to the identification of promising biomarkers that can improve diagnostic accuracy and facilitate personalized treatment approaches. As the understanding of neurological disorders deepens, the role of biomarkers in this field is expected to expand, driving growth in the biomarkers market.

By Region

North America is currently the leading region in the biomarkers market, accounting for a significant share due to the strong presence of advanced healthcare infrastructure, high research and development investments, and a robust biotechnology sector. The region's focus on personalized medicine, coupled with a high prevalence of chronic diseases, is driving the demand for biomarker-based diagnostics. The North American biomarkers market is projected to grow at a CAGR of approximately 11% from 2025 to 2035, fueled by continuous advancements in technology and an increasing number of clinical trials focusing on biomarker validation. Additionally, the presence of key industry players and strong government support for healthcare innovation further solidify North America's dominance in this market.

Europe follows closely, emerging as a prominent region in the biomarkers market due to its well-established healthcare systems and increasing investments in biomedical research. The European biomarkers market is expected to experience significant growth, driven by the rising demand for precise diagnostic tools and the growing emphasis on personalized medicine within the region. The European Union's initiatives to promote research collaboration and innovation in biomarker discovery are also contributing to market expansion. While Asia Pacific is anticipated to witness the fastest growth rate in the biomarkers market, driven by increasing healthcare expenditure and rising disease prevalence. The market dynamics in Asia Pacific are evolving rapidly, with emerging economies investing in healthcare infrastructure and research, presenting lucrative opportunities for market players.

Opportunities

One of the most promising opportunities in the biomarkers market is the increasing trend towards personalized medicine, which is revolutionizing the approach to healthcare. The shift from a one-size-fits-all treatment model to tailored therapies based on individual patient characteristics is creating a surge in demand for biomarkers that can provide critical insights into disease mechanisms and treatment responses. As healthcare providers, pharmaceutical companies, and researchers collaborate to develop innovative biomarker solutions, there is a significant opportunity for market participants to engage in the discovery and validation of novel biomarkers that enhance treatment efficacy and patient outcomes. Additionally, the growing emphasis on preventive healthcare and early disease detection is driving the demand for biomarker-based diagnostic tests, presenting further opportunities for growth and innovation in this field.

Moreover, advancements in technology, such as artificial intelligence, machine learning, and big data analytics, are creating new avenues for innovation in the biomarkers market. These technologies can enhance biomarker discovery processes, streamline data analysis, and improve diagnostic accuracy, thus facilitating faster and more effective patient management. As healthcare organizations increasingly leverage these technologies, the potential for developing cutting-edge biomarker solutions expands. The rise of telemedicine and remote patient monitoring also presents opportunities for the biomarkers market, as healthcare providers seek to deliver timely diagnostic services and treatment adjustments based on real-time patient data. Overall, the convergence of personalized medicine and technological advancements is poised to drive significant growth in the biomarkers market over the coming years.

Threats

Despite the promising growth potential of the biomarkers market, several threats could impede its progress. One of the major concerns is the stringent regulatory landscape governing biomarker testing and validation, which can pose challenges for market participants. The lengthy approval processes and evolving regulatory requirements can delay the commercialization of new biomarker-based diagnostics, hindering innovation and market entry for new players. Furthermore, the complexity of biomarker discovery and validation processes requires substantial investments in research and development, which may limit the participation of smaller companies and startups in the market. Additionally, the presence of alternative diagnostic methods and technologies may pose competitive threats to biomarker-based solutions, as healthcare providers may opt for more established diagnostic approaches.

Another significant threat to the biomarkers market is the data privacy and security concerns associated with personalized medicine and biomarker testing. As patient data is increasingly utilized for biomarker analysis and treatment decisions, ensuring the protection of sensitive information becomes paramount. Any breaches in data security can lead to a loss of trust among patients and healthcare providers, potentially impacting the adoption of biomarker solutions. Additionally, the emergence of counterfeit products and fraudulent testing services can further undermine the integrity of the biomarker market, leading to compromised patient safety and outcomes. As the market continues to evolve, addressing these threats will be crucial in ensuring the sustainable growth and acceptance of biomarker-based diagnostics.

Competitor Outlook

• Roche Diagnostics
• Abbott Laboratories
• Thermo Fisher Scientific
• Bio-Rad Laboratories
• Illumina, Inc.
• Qiagen N.V.
• Siemens Healthineers
• PerkinElmer, Inc.
• Myriad Genetics
• Agilent Technologies
• Genomic Health, Inc.
• F. Hoffmann-La Roche AG
• Medtronic plc
• Exact Sciences Corporation
• Grail, Inc.

The competitive landscape of the biomarkers market is characterized by the presence of several key players who are actively investing in research and development to enhance their product offerings. Major companies, such as Roche Diagnostics, Abbott Laboratories, and Thermo Fisher Scientific, are at the forefront of biomarker innovation, continuously developing advanced diagnostic solutions that cater to the growing demand for personalized medicine. These companies are not only focusing on the development of novel biomarker assays but also expanding their product portfolios through strategic partnerships and collaborations with research institutions and biotechnology firms. This proactive approach enables them to stay ahead of the competition and leverage emerging opportunities in the biomarkers market.

Roche Diagnostics, for instance, is a leading player in the biomarker space, known for its comprehensive range of diagnostic solutions, including advanced biomarker assays for various disease indications. The company invests significantly in research and development to explore novel biomarkers and enhance the accuracy of its diagnostic tests. Similarly, Abbott Laboratories has established itself as a key player in the biomarkers market, with a strong focus on developing innovative products that cater to the needs of healthcare providers and patients. Their robust pipeline of biomarker-related products positions them well for future growth in this dynamic market.

In addition to established players, emerging companies such as Grail, Inc. and Exact Sciences Corporation are making significant strides in the biomarkers market, particularly in the areas of cancer detection and screening. These companies are leveraging cutting-edge technologies and innovative approaches to address unmet needs in biomarker diagnostics, contributing to a competitive landscape that is increasingly focused on precision medicine. As the market continues to evolve, collaboration among industry stakeholders, including pharmaceutical companies, diagnostic laboratories, and research institutions, will be essential in driving innovation and advancing the development of novel biomarker solutions.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Grail, Inc.
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Qiagen N.V.
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Medtronic plc
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Illumina, Inc.
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Myriad Genetics
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 PerkinElmer, Inc.
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Roche Diagnostics
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Abbott Laboratories
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Agilent Technologies
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Bio-Rad Laboratories
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Genomic Health, Inc.
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Siemens Healthineers
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 F. Hoffmann-La Roche AG
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Thermo Fisher Scientific
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Exact Sciences Corporation
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Biomarkers Market, By End User
    • 6.1.1 Hospitals
    • 6.1.2 Diagnostic Laboratories
    • 6.1.3 Pharmaceutical and Biotechnology Companies
    • 6.1.4 CROs
  • 6.2 Biomarkers Market, By Application
    • 6.2.1 Diagnostics
    • 6.2.2 Drug Discovery and Development
    • 6.2.3 Personalized Medicine
  • 6.3 Biomarkers Market, By Product Type
    • 6.3.1 Consumables
    • 6.3.2 Services
    • 6.3.3 Software
  • 6.4 Biomarkers Market, By Disease Indication
    • 6.4.1 Cancer
    • 6.4.2 Cardiovascular Disorders
    • 6.4.3 Infectious Diseases
    • 6.4.4 Neurological Disorders
    • 6.4.5 Others

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Biomarkers Market by Region
  • 10.3 Asia Pacific - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 India
      • 10.3.1.2 China
      • 10.3.1.3 Japan
      • 10.3.1.4 South Korea
  • 10.4 Latin America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 Brazil
      • 10.4.1.2 Argentina
      • 10.4.1.3 Mexico
  • 10.5 North America - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 USA
      • 10.5.1.2 Canada
  • 10.6 Middle East & Africa - Market Analysis
    • 10.6.1 By Country
      • 10.6.1.1 Middle East
      • 10.6.1.2 Africa

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Biomarkers market is categorized based on

By Product Type

• Consumables
• Services
• Software

By Application

• Diagnostics
• Drug Discovery and Development
• Personalized Medicine

By End User

• Hospitals
• Diagnostic Laboratories
• Pharmaceutical and Biotechnology Companies
• CROs

By Disease Indication

• Cancer
• Cardiovascular Disorders
• Infectious Diseases
• Neurological Disorders
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Roche Diagnostics
• Abbott Laboratories
• Thermo Fisher Scientific
• Bio-Rad Laboratories
• Illumina, Inc.
• Qiagen N.V.
• Siemens Healthineers
• PerkinElmer, Inc.
• Myriad Genetics
• Agilent Technologies
• Genomic Health, Inc.
• F. Hoffmann-La Roche AG
• Medtronic plc
• Exact Sciences Corporation
• Grail, Inc.